218 Obesity Medications: What's Next in the Pipeline and Fitness Industry Impact
ace 0.10
acsm 1.00
action 0.10
afaa 1.00
afpa 1.00
bcrpa 1.00
chek 1.00
ifpa 1.00
nafc 0.10
nasm 0.10
ncep 1.00
ncsf 0.50
nesta 0.10
neta 1.00
nfpt 0.20
niew 0.10
nspa 1.00
Research on obesity medications is rapidly advancing and constantly changing, whether through new evidence of the benefits of these agents beyond weight loss or announcements of new pharmacotherapies in the research and development pipeline. Learn what is cutting-edge, including–and beyond–“GLP-1s.” Attendees will hear the latest updates and potential impacts on the fitness industry and clients, highlighting the evidence ready for prime time and the unknowns surrounding these highly effective agents.
Session 218
Share this course